We have observed
3 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after December 14, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
RODENT CONTROL DEVICE
CXCL12 (CHEMOKINE (C-X-C MOTIF) LIGAND 12) AND IGFBP2 INHIBITORS FOR THE APPLICATION IN THE TREATMENT OF DIABETES MELLITUS ASSOCIATED PANCREATIC CANCER
CONTINUOUS FLOW PEPTIDE SYNTHESIS